Collplant Biotechnologies Ltd is a biotechnology company focused on developing innovative solutions for tissue regeneration and wound healing
The company harnesses its proprietary recombinant human collagen technology, which is designed to support the body’s natural healing processes. Collplant’s primary applications include products aimed at treating various medical conditions, including skin wounds, surgical recovery, and orthopedic injuries. By leveraging its advanced biotechnological capabilities, Collplant aims to improve patient outcomes and offer alternatives to traditional treatments in the regenerative medicine field.
CLGN stock results show that CollPlant Biotechnologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
CLGN stock results show that CollPlant Biotechnologies met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
CLGN stock results show that CollPlant Biotechnologies missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Companies Reporting Before The Bell • CollPlant Biotechnologies (NASDAQCLGN) is likely to report quarterly loss at $0.13 per share on revenue of $3.50 million.
CollPlant Biotechnologies Ltd (NASDAQCLGN) shares are trading higher Monday after the company announced it achieved a milestone in its product collaboration agreement with AbbVie Inc (NYSE:
Gainers Benitec Biopharma Inc. (NASDAQBNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy.
Companies Reporting Before The Bell • Bank of Nova Scotia (NYSEBNS) is estimated to report quarterly earnings at $1.78 per share on revenue of $8.09 billion.
